These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37098360)

  • 1. Posttransplant cyclophosphamide contributes to the impairment of the graft-versus-leukemia effect and the amelioration of graft-versus-host disease with the suppression of alloreactive T cells in a murine stem cell transplant model.
    Makuuchi Y; Nakashima Y; Nishimoto M; Koh H; Hino M; Nakamae H
    Exp Hematol; 2023 Jul; 123():56-65. PubMed ID: 37098360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4
    Hadjis AD; Nunes NS; Khan SM; Fletcher RE; Pohl AP; Venzon DJ; Eckhaus MA; Kanakry CG
    Front Immunol; 2022; 13():796349. PubMed ID: 35242129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding.
    Nunes NS; Kanakry CG
    Front Immunol; 2019; 10():2668. PubMed ID: 31849930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.
    Makanga DR; Guillaume T; Willem C; Legrand N; Gagne K; Cesbron A; Gendzekhadze K; Peterlin P; Garnier A; Le Bourgeois A; Béné MC; Chevallier P; Retière C
    J Immunol; 2020 Sep; 205(5):1441-1448. PubMed ID: 32747504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice.
    Cuthbertson P; Button A; Sligar C; Elhage A; Vine KL; Watson D; Sluyter R
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-transplant cyclophosphamide limits reactive donor T cells and delays the development of graft-versus-host disease in a humanized mouse model.
    Adhikary SR; Cuthbertson P; Nicholson L; Bird KM; Sligar C; Hu M; O'Connell PJ; Sluyter R; Alexander SI; Watson D
    Immunology; 2021 Oct; 164(2):332-347. PubMed ID: 34021907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression.
    Wachsmuth LP; Patterson MT; Eckhaus MA; Venzon DJ; Gress RE; Kanakry CG
    J Clin Invest; 2019 Mar; 129(6):2357-2373. PubMed ID: 30913039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced dose of PTCy followed by adjuvant α-galactosylceramide enhances GVL effect without sacrificing GVHD suppression.
    Nakamura M; Meguri Y; Ikegawa S; Kondo T; Sumii Y; Fukumi T; Iwamoto M; Sando Y; Sugiura H; Asada N; Ennishi D; Tomida S; Fukuda-Kawaguchi E; Ishii Y; Maeda Y; Matsuoka KI
    Sci Rep; 2021 Jun; 11(1):13125. PubMed ID: 34162921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.
    Ganguly S; Ross DB; Panoskaltsis-Mortari A; Kanakry CG; Blazar BR; Levy RB; Luznik L
    Blood; 2014 Sep; 124(13):2131-41. PubMed ID: 25139358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current state of graft-versus-host disease prophylaxis with PTCy for allogeneic hematopoietic stem cell transplantation].
    Nakamae H
    Rinsho Ketsueki; 2024; 65(5):391-400. PubMed ID: 38825519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects.
    Patterson MT; Khan SM; Nunes NS; Fletcher RE; Bian J; Hadjis AD; Eckhaus MA; Mendu SK; de Paula Pohl A; Venzon DJ; Choo-Wosoba H; Ishii K; Qin H; Fry TJ; Cam M; Kanakry CG
    Blood; 2023 Feb; 141(6):659-672. PubMed ID: 36201744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved NK Cell Recovery Following Use of PTCy or Treg Expanded Donors in Experimental MHC-Matched Allogeneic HSCT.
    Wolf D; Barreras H; Copsel SN; Komanduri KV; Levy RB
    Transplant Cell Ther; 2022 Jun; 28(6):303.e1-303.e7. PubMed ID: 35302008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant.
    Zhao C; Bartock M; Jia B; Shah N; Claxton DF; Wirk B; Rakszawski KL; Nickolich MS; Naik SG; Rybka WB; Ehmann WCC; Hohl RJ; Valentin J; Bernas-Peterson M; Gerber EM; Zimmerman M; Mierski JA; Mineishi S; Zheng H
    J Hematol Oncol; 2022 May; 15(1):64. PubMed ID: 35590334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Battipaglia G; Labopin M; Hamladji RM; Blaise D; Chevallier P; Brissot E; Gerbitz A; Socié G; Afanasyev B; Ciceri F; Meijer E; Koc Y; Cornelissen JJ; Huynh A; Ozdogu H; Maertens J; Paul F; Labussière-Wallet H; Ruggeri A; Aljurf M; Bazarbachi A; Savani B; Nagler A; Mohty M
    Cancer; 2021 Jan; 127(2):209-218. PubMed ID: 33119152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors.
    Oran B; Garcia-Manero G; Saliba RM; Alfayez M; Al-Atrash G; Ciurea SO; Jabbour EJ; Mehta RS; Popat UR; Ravandi F; Alousi AM; Kadia TM; Konopleva M; DiNardo CD; Rezvani K; Shpall EJ; Sharma P; Kantarjian HM; Champlin RE; Daver N
    Cancer; 2020 May; 126(10):2193-2205. PubMed ID: 32125707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation.
    Massoud R; Gagelmann N; Fritzsche-Friedland U; Zeck G; Heidenreich S; Wolschke C; Ayuk F; Christopeit M; Kröger N
    Haematologica; 2022 Apr; 107(4):857-867. PubMed ID: 33832208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flt-3L Expansion of Recipient CD8α
    Markey KA; Kuns RD; Browne DJ; Gartlan KH; Robb RJ; Martins JP; Henden AS; Minnie SA; Cheong M; Koyama M; Smyth MJ; Steptoe RJ; Belz GT; Brocker T; Degli-Esposti MA; Lane SW; Hill GR
    Clin Cancer Res; 2018 Apr; 24(7):1604-1616. PubMed ID: 29367429
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.